Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 1475 record(s)

Req # A-2022-000903

Adverse Drug Reaction (ADR) for VYVANSE. Report number: 001004031. ADR for GAMMAGARD LIQUID. Report number: 001000322. ADRs for Immunoglobulin (human). Report numbers: E2B_05580252, E2B_05524240, E2B_05586458, E2B_05548682, E2B_05552929, E2B_05600522, 001002475. ADR for Antihemophilic factor (human). Report number: E2B_05551873.

Organization: Health Canada

148 page(s)
December 2022

Req # A-2022-000905

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-114621-66.

Organization: Health Canada

8 page(s)
December 2022

Req # A-2022-000911

Adverse Drug Reactions (ADRs). Report numbers: E2B_05047204, E2B_05047236, E2B_05047237, E2B_05047240, E2B_05047243, E2B_05047248, E2B_05047264, E2B_05047358, E2B_05047361, E2B_05047370.

Organization: Health Canada

169 page(s)
December 2022

Req # A-2022-000914

Adverse Drug Reactions (ADRs). Report numbers: E2B_05609302, E2B_05046447, E2B_05046450, E2B_05046452, E2B_05046473, E2B_05047356, E2B_05047109.

Organization: Health Canada

137 page(s)
December 2022

Req # A-2022-000937

Adverse Drug Reactions (ADRs). Report numbers: E2B_05628332, E2B_05636323, E2B_05654468, E2B_05674614.

Organization: Health Canada

116 page(s)
December 2022

Req # A-2022-000951

Adverse Drug Reactions (ADRs). Report numbers: E2B_05032770, E2B_05032778, E2B_05032780, E2B_05032786, E2B_05041435, E2B_05041535, E2B_05041668, E2B_05040772, E2B_05041693, E2B_05041685.

Organization: Health Canada

178 page(s)
December 2022

Req # A-2022-000984

Adverse Drug Reaction (ADR). Report number: E2B_05694123.

Organization: Health Canada

22 page(s)
December 2022

Req # A-2022-001007

Adverse Drug Reaction (ADR) for Pantoprazole sodium. Report number: E2B_05661818. ADRs for Lansoprazole. Report numbers: E2B_05686167, E2B_05680047.

Organization: Health Canada

78 page(s)
December 2022

Req # A-2022-001012

Adverse Drug Reactions (ADRs) for Zenhale. Report numbers: E2B_01412713, E2B_01511788, E2B_01578394, E2B_01586148, E2B_01619809, E2B_01650004.

Organization: Health Canada

143 page(s)
December 2022

Req # A-2022-001071

Adverse Drug Reaction (ADR) for . Report number: 001005758.

Organization: Health Canada

3 page(s)
December 2022
Date modified: